Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with 64Cu-NOTA-TRC105

Orbay, Hakan; Zhang, Yin; Valdovinos, Hector F.; Song, Guoqing; Hernandez, Reinier; Theuer, Charles P.; Hacker, Timothy A.; Nickles, Robert J.; Cai, Weibo
January 2014
American Journal of Nuclear Medicine & Molecular Imaging;2014, Vol. 4 Issue 1, p1
Academic Journal
Biological changes following myocardial infarction (MI) lead to increased secretion of angiogenic factors that subsequently stimulate the formation of new blood vessels as a compensatory mechanism to reverse ischemia. The goal of this study was to assess the role of CD105 expression during MI-induced angiogenesis by positron emission tomography (PET) imaging using 64Cu-labeled TRC105, an anti-CD105 monoclonal antibody. MI was induced by ligation of the left anterior descending (LAD) artery in female rats. Echocardiography and 18F-fluoro-2-deoxy-D-glucose (18F-FDG) PET scans were performed on post-operative day 3 to confirm the presence of MI in the infarct group and intact heart in the sham group, respectively. Ischemia-induced angiogenesis was non-invasively monitored with 64Cu-NOTA-TRC105 (an extensively validated PET tracer in our previous studies) PET on post-operative days 3, 10, and 17. Tracer uptake in the infarct zone was highest on day 3 following MI, which was significantly higher than that in the sham group (1.41 ± 0.45 %ID/g vs 0.57 ± 0.07 %ID/g; n=3, p<0.05). Subsequently, tracer uptake in the infarct zone decreased over time to the background level on day 17, whereas tracer uptake in the heart of sham rats remained low at all time points examined. Histopathology documented increased CD105 expression following MI, which corroborated in vivo findings. This study indicated that PET imaging of CD105 can be a useful tool for MI-related research, which can potentially improve MI patient management in the future upon clinical translation of the optimized PET tracers.


Related Articles

  • Emerging Role of Apelin as a Therapeutic Target in Cancer: A Patent Review. Rayalam, Srujana; Della-Fera, Mary A.; Kasser, Thomas; Warren, William; Baile, Clifton A. // Recent Patents on Anti-Cancer Drug Discovery;Sep2011, Vol. 6 Issue 3, p367 

    Since tumors cannot grow or spread without forming new blood vessels, inhibiting angiogenesis is an excellent approach for the treatment of cancer. Further, inhibitors of angiogenesis have mild side effects since they act on endothelial cells, which eliminate the possibility of developing...

  • In vivo characterization of Ga-NOTA-VEGF for the imaging of VEGF receptor expression in U87MG tumor xenograft models. Kang, Choong; Kim, Sung-Min; Koo, Hyun-Jung; Yim, Min; Lee, Kyung-Han; Ryu, Eun; Choe, Yearn // European Journal of Nuclear Medicine & Molecular Imaging;Feb2013, Vol. 40 Issue 2, p198 

    Purpose: Vascular endothelial growth factor receptors (VEGFRs) are associated with tumor growth and induction of tumor angiogenesis and are known to be overexpressed in various human tumors. In the present study, we prepared and evaluated Ga-1,4,7-triazacyclononane-1,4,7-triacetic acid-benzyl...

  • VEGF blockade: Optimizing chemotherapy drug uptake. FURLOW, BRYANT // Oncology Nurse Advisor;Mar/Apr2012, Vol. 3 Issue 2, p22 

    No abstract available.

  • Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer. Rossi, A.; Maione, P.; Ferrara, M. L.; Sacco, P. C.; Schettino, C.; Bareschino, M. A.; Gridelli, C. // Current Medicinal Chemistry;Oct2009, Vol. 16 Issue 30, p3919 

    Most patients diagnosed with non-small cell lung cancer (NSCLC) have advanced disease. Chemotherapy has apparently reached a plateau of effectiveness in improving survival in this subgroup of patients. Considerable efforts have been initiated to identify novel targets for new biological agents...

  • Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products. Wahl, O.; Oswald, M.; Tretzel, L.; Herres, E.; Arend, J.; Efferth, T. // Current Medicinal Chemistry;Jul2011, Vol. 18 Issue 21, p3136 

    No abstract available.

  • VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Giacca, M; Zacchigna, S // Gene Therapy;Jun2012, Vol. 19 Issue 6, p622 

    Despite the enormous progress made in terms of prevention and early intervention, a pressing need remains to develop innovative therapeutic strategies for ischemic cardiovascular disorders, including acute myocardial infarction, chronic cardiac ischemia, peripheral artery disease and stroke. The...

  • Circulating Endothelial Progenitor Cells and Coronary Collaterals in Patients with Non-ST Segment Elevation Myocardial Infarction. Lev, Eli I.; Kleiman, Neal S.; Birnbaum, Yochai; Harris, David; Korbling, Martin; Estrov, Zeev // Journal of Vascular Research;2005, Vol. 42 Issue 5, p408 

    Background: Endothelial progenitor cells (EPCs) are bone marrow-derived cells that are augmented in response to ischemia and incorporated into neovascularization sites. We sought to determine whether circulating EPCs are related to collateral formation following non-ST segment elevation...

  • PET monitoring angiogenesis of infarcted myocardium after treatment with vascular endothelial growth factor and bone marrow mesenchymal stem cells. Cai, Mengting; Ren, Lei; Yin, Xiaoqin; Guo, Zhide; Li, Yesen; He, Tingting; Tang, Yongxiang; Long, Tingting; Liu, Yutao; Liu, Gang; Zhang, Xianzhong; Hu, Shuo // Amino Acids;Mar2016, Vol. 48 Issue 3, p811 

    Angiogenesis is a key factor for post-ischemic repair of the infarcted myocardium. This study aims to monitor angiogenesis of infarcted myocardium with a positron emission tomography (PET) imaging agent, F-alfatide II (F-AlF-NOTA-E[PEG-c(RGDfk)]), targeting αβ integrin after treatment with...

  • Differentiation of endothelial cells from human umbilical cord blood AC133-CD14+ cells. Kim, Shin-Young; Park, So-Yeon; Kim, Jin; Kim, Jin-Woo; Kim, Moon; Yang, Jae; Kim, Joo; Choi, Kyu-Hong; Kim, Seung; Ryu, Hyun-Mee; Kim, Jin Mi; Kim, Moon Young; Yang, Jae Hyug; Kim, Joo Oh; Kim, Seung Bo // Annals of Hematology;Jul2005, Vol. 84 Issue 7, p417 

    Endothelial progenitor cells (EPCs) participate in neovascularization and are consistent with postnatal vasculogenesis. In vitro, they differentiate into endothelial cells (ECs). Prior reports have suggested that circulating human AC133+ cells have the capacity to differentiate into ECs as...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics